The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nikolaeva M.G.

Obstetrics and Gynecology Department with the course of Supplementary Vocational Education in FSBEI of Higher Education «Altai State Medical University» Barnaul, Russia

Yasafova N.N.

Altai Regional Clinical Hospital, Barnaul, Russia

Momot A.P.

Altai Branch of the FSBI «National Research Center for Hematology», Barnaul, Russia

Zaĭnulina M.S.

Kafedra akusherstva i ginekologii Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. akad. I.P. Pavlova;
NII akusherstva i ginekologii im. D.O. Otta RAMN, Sankt-Peterburg

Momot K.A.

Altai Regional Clinical Hospital, Barnaul, Russia

Taranenko I.A.

Altai Regional Clinical Hospital, Barnaul, Russia

Phenotypic Manifestations of Prothrombin Gene Mutation, Genotype, in Women of Reproductive Age

Authors:

Nikolaeva M.G., Yasafova N.N., Momot A.P., Zaĭnulina M.S., Momot K.A., Taranenko I.A.

More about the authors

Journal: Journal of Venous Disorders. 2019;13(4): 285‑293

DOI: 10.17116/flebo201913041285

Read: 4544 times

Download PDF (RU)
Contact the author
Table of contents

PHENOTYPIC MANIFESTATIONS OF PROTHROMBIN GENE MUTATION, GENOTYPE, IN WOMEN OF REPRODUCTIVE AGE
PHENOTYPIC MANIFESTATIONS OF PROTHROMBIN GENE MUTATION, GENOTYPE, IN WOMEN OF REPRODUCTIVE AGE

To cite this article:

Nikolaeva MG, Yasafova NN, Momot AP, Zaĭnulina MS, Momot KA, Taranenko IA. Phenotypic Manifestations of Prothrombin Gene Mutation, Genotype, in Women of Reproductive Age. Journal of Venous Disorders. 2019;13(4):285‑293. (In Russ.)
https://doi.org/10.17116/flebo201913041285

 
Подписка 2026 Флебология (Journal of Venous Disorders)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sagi­ttal sinus thro­mbosis during pregnancy with the deve­lopment of ischemic stroke. Russian Bulletin of Obstetrician-Gynecologist. 2025;(5):87-91
Abstract:

Objective — to analyse association of prothrombin (factor II) activity in women with prothrombin gene mutation, F2(20210)GA genotype, and the types of thrombotic events. Material and methods. A prospective clinical cohort study enrolled 290 women of reproductive age. The study group included 140 patients with F2(20210)GA genotype, the control group — 150 women with F2(20210)GG genotype. Results. Prothrombin F2(G20210)GA mutation is associated with thrombosis compared to wild type F2(20210)GG genotype (RR=17.1; p<0.0001) and characterized by both venous (66.7%) and arterial thrombosis (33.3%). The threshold of prothrombin activity (174.8%) for F2(20210)GA genotype was calculated. This value is useful to predict the risk of thrombotic events with an accuracy of 90.4%. Conclusion. F2(G20210)GA mutation manifests as venous and arterial thromboses in women of reproductive age mainly in case of supra-threshold increase of prothrombin (factor II) activity. Therefore, groups of low and high thrombotic risk may be distinguished regardless extra-genital diseases in order to determine the feasibility of prevention of thrombosis.

Keywords:

prothrombin gene mutation
F2(20210)GA genotype
venous and arterial thromboses
prothrombin activity
thromboprophylaxis

Authors:

Nikolaeva M.G.

Obstetrics and Gynecology Department with the course of Supplementary Vocational Education in FSBEI of Higher Education «Altai State Medical University» Barnaul, Russia

Yasafova N.N.

Altai Regional Clinical Hospital, Barnaul, Russia

Momot A.P.

Altai Branch of the FSBI «National Research Center for Hematology», Barnaul, Russia

Zaĭnulina M.S.

Kafedra akusherstva i ginekologii Sankt-Peterburgskogo gosudarstvennogo meditsinskogo universiteta im. akad. I.P. Pavlova;
NII akusherstva i ginekologii im. D.O. Otta RAMN, Sankt-Peterburg

Momot K.A.

Altai Regional Clinical Hospital, Barnaul, Russia

Taranenko I.A.

Altai Regional Clinical Hospital, Barnaul, Russia

Close metadata

References:

  1. Bokeriya LA, Zatevakhin II, Kirienko AI. Rossiiskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhnenii. Flebologiya. 2015;4:1-51. (In Russ.)
  2. Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006—2010. Obstet Gynecol. 125 (1):5-12. https://doi.org/10.1097/AOG.0000000000000564
  3. Royal College of Obstetricians and Gynaecologists (2015) Green-top Guideline No. 37b. Thromboembolic disease in pregnancy and the puerperium: acute management. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/
  4. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variant in the 30-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased in venous thrombosis. Blood. 1996;88:3698-3703.
  5. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism — pooled analysis of 8 casecontrol studies including 2310 cases and 3204 controls. Study group for pooledanalysis in venous thromboembolism. Thromb Haemost. 2001;86(3):809-816.
  6. Gehring NH, Frede U, Neu-Yilik G, Hundsdoerfer P, Vetter B, Hentze MW, Kulozik AE. Increased efficiency of mRNA 3’ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nature Genetics. 2001;28(4):389-392. https://doi.org/10.1038/ng578
  7. Magnusson S. The Enzymes. Ed. PD Boyer. Vol. III. New York: Academic Press, 1971;277-321.
  8. Crawley JT, Zanardelli S, Chion CK, Lane DA. The central role of thrombin in hemostasis. J Thromb Haemost. 2007;5(Suppl 1):95-101.
  9. Spector EB, Grody WW, Matteson CJ, Palomaki GE, Bellissimo DB, Wolff DJ, Bradley LA, Prior TW, Feldman G, Popovich BW, Watson MS, Richards CS. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G > A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet. Med. 7(6):444-453. https://doi.org/10.1097/01.gim.0000172641.57755.3a
  10. Dziadosz M, Baxi LV. Global prevalence of prothrombin gene mutation G20210A and implications in women’s health: a systematic review. Blood Coagul Fibrinolysis. 2016;27(5):481-489. https://doi.org/10.1097/MBC.0000000000000562
  11. Franco RF, Reitsma PH. Genetic risk factors of venous thrombosis. Hum Genet. 2001;109(4):369-384. https://doi.org/10.1007/s004390100593
  12. Bosler D, Mattson J, Crisan D. Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. J Mol Diagn. 2006;8(4):420-425. https://doi.org/10.2353/jmoldx.2006.060014
  13. Alatri A, Franchi F, Moia M. Homozygous G20210A prothrombin gene mutation without thromboembolic events: a case report. Thromb Haemost. 1998;80:1028-1029.
  14. Boinot C, Borgel D, Kitzis A, Guicheteau M, Aiach M, Alhenc-Gelas M. Familial thrombophilia is an oligogenetic disease: involvement of the prothrombin G20210A, PROC and PROS gene mutations. Blood Coagul Fibrinolysis. 2003;14:191-196. https://doi.org/10.1097/00001721-200302000-00012
  15. Klein L, Bhardwaj V, Gebara B. Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype. J Perinatol. 2004;24:797-799. https://doi.org/10.1038/sj.jp.7211187
  16. Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost. 2007;5:98-101. https://doi.org/10.1111/j.1538-7836.2006.02291.x
  17. Profilaktika venoznykh tromboembolicheskikh oslozhnenii v akusherstve i ginekologii. Klinicheskie rekomendatsii (protokol lecheniya) pis’mo Ministerstva zdravookhraneniya Rossiiskoi federatsii on 27 maya 2014 g. №15-4/10/2-3792. (In Russ.)
  18. Jacobsen AF, Dahm A, Bergrem A, Jacobsen EM, Sandset PM. Risk of venous thrombosis in pregnancy among carriers of the factor V Leiden and the prothrombin gene G20210A polymorphisms. J Thromb Haemost. 2010;8(11):2443-2449. https://doi.org/10.1111/j.1538-7836.2010.04038.x
  19. Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, Bergqvist D, Bonnar J, Caprini JA, Carter C, Conard J, Eklof B, Elalamy I, Gerotziafas G, Geroulakos G, Giannoukas A, Greer I, Griffin M, Kakkos S, Lassen MR, Lowe GD, Markel A, Prandoni P, Raskob G, Spyropoulos AC, Turpie AG, Walenga JM, Warwick D. Prevention and treatment of venous thromboembolism. International Consensus Statement. International Angiology. 2013;32(2):111-260.
  20. Bank I, Libourel EJ, Middeldorp S, Van Pampus EC, Koopman MM, Hamulyak K, Prins MH, van der Meer J, Buller HR. Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med. 2004;164:1932-1937. https://doi.org/10.1001/archinte.164.17.1932
  21. Segal JB, Brotman DJ, Necochea AJ, Emadi A, Samal L, Wilson LM, Crim MT, Bass EB. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA. 2009;301:2472-2485. https://doi.org/10.1001/jama.2009.853
  22. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344:1527-1535. https://doi.org/10.1056/NEJM200105173442007
  23. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med. 2004;164(18):1965-1976. https://doi.org/10.1001/archinte.164.18.1965
  24. Wu O, Robertson L, Langhorne P, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Brenkel I, Regan L, Greer IA. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The thrombosis: risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost. 2005;94(1):17-25. https://doi.org/10.1160/TH04-11-0759
  25. Simone B, De Stefano V, Leoncini E, Zacho J, Martinelli I, Emmerich J, Rossi E, Folsom AR, Almawi WY, Scarabin PY, den Heijer M, Cushman M, Penco S, Vaya A, Angchaisuksiri P, Okumus G, Gemmati D, Cima S, Akar N, Oguzulgen KI, Ducros V, Lichy C, Fernandez-Miranda C, Szczeklik A, Nieto JA, Torres JD, Le Cam-Duchez V, Ivanov P, Cantu-Brito C, Shmeleva VM, Stegnar M, Ogunyemi D, Eid SS, Nicolotti N, De Feo E, Ricciardi W, Boccia S. Risk of venous thromboembolism associated with single and combined effects of factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a metaanalysis involving over 11,000 cases and 21,000 controls. Eur J Epidemiol. 2013;28(8):621-647. https://doi.org/10.1007/s10654-013-9825-8
  26. Daly E, Vessey MP, Painter R, Hawkins MM. Case-control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet. 1996;348:1027. https://doi.org/10.1016/S0140-6736(96)24041-3
  27. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348(9033):983-987. https://doi.org/10.1016/S0140-6736(96)07308-4
  28. Varga EA, Moll S. Cardiology patient pages. Prothrombin 20210 mutation (factor II mutation). Circulation. 2004;110(3):e15-e18. https://doi.org/10.1161/01.CIR.0000135582.53444.87
  29. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M, Sandmann W, Zotz RB. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342(6):374-380. https://doi.org/10.1056/NEJM200002103420602
  30. Martinelli I, De Stefano V, Taioli E, Paciaroni K, Rossi E, Mannucci PM. Inherited thrombophilia and first venous thromboembolism during pregnancy and puerperium. Thromb Haemost. 2002;87(5):791-795.
  31. Momot AP. The problem of thrombophilia in clinical practice. Russian Journal of Children Hematology and Oncology. 2015;1:36-48. (In Russ.) https://doi.org/10.17650/2311-1267-2015-1-36-48
  32. Hertzberg MS. Genetic testing for thrombophilia mutations. Semin Thromb Hemost. 2005;31:33-38. https://doi.org/10.1055/s-2005-863803
  33. Nikolaeva MG, Momot KA, Yasafova NN, Momot AP, Khorev NG. Rol` priobretennykh faktorov riska venoznykh tromboembolicheskikh oslozhneniy u zhenshcin reproduktivnogo vozrasta pri nositelstve Leydenskoy mutatsii faktora V. Flebologiya. 2018;12(3):101-108. (In Russ.) https://doi.org/10.17116/flebo2018123101
  34. Momot AP, Nikolaeva MG, Zainulina MS. The Main Causes of Thrombotic Events in Carriage of Leiden Mutation in Women of Reproductive Age. J Hematol Thromb Dis. 2018;6:296. https://doi.org/10.4172/2329-8790.1000296
  35. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE clinical guideline 92. London: NICE; 2010.
  36. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease (review). Thromb Haemost. 2001;85:584-595.
  37. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol. 2004;61(11):1652-1661. https://doi.org/10.1001/archneur.61.11.1652
  38. Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P. Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants. PLoS One. 2010;5(2):e9136. https://doi.org/10.1371/journal.pone.0009136
  39. Korchagin VI, Mironov KO, Dribnokhodova OP, Maksimova MYu, Illarioschkin SN, Tanashyan MM, Platonov AE, Shipulin GA, Raskurazhev AA, Piradov MA. The role of genetic factors in the development of individual predisposition to ischemic stroke. Human Physiology. 2017;43(8):886-897.
  40. Rallidis LS, Gialeraki A, Tsirebolos G, Tsalavoutas S, Rallidi M, Iliodromitis E. Prothrombotic genetic risk factors in patients with very early ST-segment elevation myocardial infarction. J Thromb Thrombolysis. 2017;44(2):267-273. https://doi.org/10.1007/s11239-017-1520-2
  41. Medical eligibility criteria for contraceptive use. 3rd ed. World Health Organization, 2004; ISNB 92 4 156266 8 (NLM classification: WP 630).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.